Cambridge, England, 2 November 2020 – Exhalation Technology (ETL), a Cambridge, UK-based company, announced the start of a large clinical study on humans with its novel CoronaCheck™ diagnostic test for Covid-19 in exhaled breath condensate (EBC). This is a rapid test (aims for a result in under 5 minutes) of high specificity and sensitivity for Covid-19, meeting the need for efficient and accurate testing in a wide range of environments including hospitals, airports, retail outlets, schools and similar spaces. ETL have developed CoronaCheck™, a rapid antigen test for Covid-19 virus, exploiting their expertise in exhaled breath diagnostics. Before the initiation of clinical trials in the UK,
